Terms: = Thyroid cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Treatment
255 results:
1. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
Chen Y; Xiao X; Hu G; Liu R; Xue J
J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
[TBL] [Abstract] [Full Text] [Related]
2. Biological functions of LncRNA SNHG14 in the development of thyroid cancer cells via targeting miR-206.
Sang Y; Min R; Huang T; Zhang J
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):77-84. PubMed ID: 38678623
[TBL] [Abstract] [Full Text] [Related]
3. AKR1C3 silencing inhibits autophagy-dependent glycolysis in thyroid cancer cells by inactivating erk signaling.
Gao Y; Tao W; Wang S; Duan R; Zhang Z
Drug Dev Res; 2024 Feb; 85(1):e22142. PubMed ID: 38349266
[TBL] [Abstract] [Full Text] [Related]
4. thyroid dysfunction caused by exposure to environmental endocrine disruptors and the underlying mechanism: A review.
He J; Xu J; Zheng M; Pan K; Yang L; Ma L; Wang C; Yu J
Chem Biol Interact; 2024 Mar; 391():110909. PubMed ID: 38340975
[TBL] [Abstract] [Full Text] [Related]
5. CMTM 6 promotes the development of thyroid cancer by inhibiting NIS activity through activating the MAPK signaling pathway.
Chen X; Shen H; Liu H; Tan L; Zhang N
Funct Integr Genomics; 2024 Jan; 24(1):10. PubMed ID: 38221563
[TBL] [Abstract] [Full Text] [Related]
6. SLC35A2 expression drives breast cancer progression via erk pathway activation.
Yang X; Tao Y; Xu Y; Cai W; Shao Q
FEBS J; 2024 Apr; 291(7):1483-1505. PubMed ID: 38143314
[TBL] [Abstract] [Full Text] [Related]
7. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.
Bahar ME; Kim HJ; Kim DR
Signal Transduct Target Ther; 2023 Dec; 8(1):455. PubMed ID: 38105263
[TBL] [Abstract] [Full Text] [Related]
8. FLOT1 promotes gastric cancer progression and metastasis through BCAR1/erk signaling.
Wang R; Huang W; Cai K; Xiao S; Zhang W; Hu X; Guo J; Mao L; Yuan W; Xu Y; Chen Z; Chen Z; Lai C
Int J Biol Sci; 2023; 19(16):5104-5119. PubMed ID: 37928269
[TBL] [Abstract] [Full Text] [Related]
9. Tetraspanin 1 regulates papillary thyroid tumor growth and metastasis through c-Myc-mediated glycolysis.
Han J; Xie C; Liu B; Wang Y; Pang R; Bi W; Sheng R; He G; Kong L; Yu J; Ding Z; Chen L; Jia J; Zhang J; Nie C
Cancer Sci; 2023 Dec; 114(12):4535-4547. PubMed ID: 37750019
[TBL] [Abstract] [Full Text] [Related]
10. ADAMTS12 promotes oxaliplatin chemoresistance and angiogenesis in gastric cancer through VEGF upregulation.
Jiang Y; Huang J; Huang Z; Li W; Tan R; Li T; Chen Z; Tang X; Zhao Y; Qiu J; Li C; Chen H; Yang Z
Cell Signal; 2023 Nov; 111():110866. PubMed ID: 37619822
[TBL] [Abstract] [Full Text] [Related]
11. [Clinicopathological features of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma].
Zhu M; Li J; Zheng WH; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2023 Aug; 52(8):820-826. PubMed ID: 37527987
[No Abstract] [Full Text] [Related]
12. An Insight on Synergistic Anti-cancer Efficacy of Biochanin A and Sulforaphane Combination Against Breast cancer.
Li J; Xu J; Sun Y; Fu R; Ye D
Appl Biochem Biotechnol; 2024 Feb; 196(2):992-1007. PubMed ID: 37289419
[TBL] [Abstract] [Full Text] [Related]
13. Supramolecular nanofibers co-loaded with dabrafenib and doxorubicin for targeted and synergistic therapy of differentiated thyroid carcinoma.
Chen P; Cai X; Mu G; Duan Y; Jing C; Yang Z; Yang C; Wang X
Theranostics; 2023; 13(7):2140-2153. PubMed ID: 37153748
[No Abstract] [Full Text] [Related]
14. RNF125 attenuates hepatocellular carcinoma progression by downregulating SRSF1-erk pathway.
Feng Z; Ke S; Wang C; Lu S; Xu Y; Yu H; Li Z; Yin B; Li X; Hua Y; Qian B; Bai M; Fu Y; Zhang Y; Wu Y; Ma Y
Oncogene; 2023 Jun; 42(24):2017-2030. PubMed ID: 37142680
[TBL] [Abstract] [Full Text] [Related]
15. TESC promotes differentiated thyroid cancer development by activating erk and weakening NIS and radioiodine uptake.
Guo Y; Cai Y; Song F; Zhu L; Hu Y; Liu Y; Ma W; Ge J; Zeng Q; Ding L; Li L; Zheng G; Ge M
Endocrine; 2023 Sep; 81(3):503-512. PubMed ID: 37020077
[TBL] [Abstract] [Full Text] [Related]
16. RNF150 suppresses papillary thyroid carcinoma with ASK1 ubiquitination presenting a direct target via inactivating p38 signaling axis.
Deng W; Wu J; Zheng W; Wang Q; Li D; Kuang H
Cell Biol Int; 2023 Jul; 47(7):1198-1208. PubMed ID: 36950779
[TBL] [Abstract] [Full Text] [Related]
17. [Duodenal bleeding due to metastasis from lung adenocarcinoma controlled by radiotherapy: A case report and literature review].
Severin S; Terrones Munoz V; Meert N; Peche R
Rev Mal Respir; 2023 Apr; 40(4):359-365. PubMed ID: 36868976
[TBL] [Abstract] [Full Text] [Related]
18. Disulfiram/Cu Kills and Sensitizes
Xie J; Liu J; Zhao M; Li X; Wang Y; Zhao Y; Cao H; Ji M; Chen M; Hou P
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834830
[No Abstract] [Full Text] [Related]
19. Overexpression of the pro-protein convertase furin predicts prognosis and promotes papillary thyroid carcinoma progression and metastasis through RAF/MEK signaling.
Poyil PK; Siraj AK; Padmaja D; Parvathareddy SK; Diaz R; Thangavel S; Begum R; Haqawi W; Al-Mohanna FH; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Mol Oncol; 2023 Jul; 17(7):1324-1342. PubMed ID: 36799665
[TBL] [Abstract] [Full Text] [Related]
20. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.
Wang J; Yu H; Dong W; Zhang C; Hu M; Ma W; Jiang X; Li H; Yang P; Xiang D
Gastroenterology; 2023 May; 164(6):990-1005. PubMed ID: 36764493
[TBL] [Abstract] [Full Text] [Related]
[Next]
